Scientists in the Garner laboratory have recently published some exciting findings regarding improved cognitive performance in a mouse model of Down syndrome. Using several different drugs, scientists were able to restore cognitive performance in mice to almost normal levels. To their surprise, improved cognitive performance persisted, even after the drug treatment had been terminated.

These research results shed new light on potential mechanisms underlying impaired cognition in Down syndrome and may provide novel strategies for therapeutic possibilities. While this is very encouraging news, it is important to keep in mind that these studies were carried out in animals. The safety and efficacy of the drugs will have to be carefully assessed.

If you have any questions about this study, please contact us at dsresearch@med.stanford.edu. Please be advised that the Down syndrome clinic at the Lucile Packard Children's Hospital is not involved in this research.

For more information see Down Syndrome News and Views.

Recent article in Stanford School of Medicine Magazine: Got (chocolate) Milk?

Brock Grill, PhD
Christoph Maas, PhD
Matt Anderson, Undergraduate Stanford University

Fabian Fernandez successfully defended his doctoral thesis and is heading for a post-doc in Colorado.
More »